A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
暂无分享，去创建一个
Wei Huang | Wenteng Chen | Jing-kang Shen | Zhixiong Xiang | H. Miao | Yong Zhang | Yongping Yu | Jing Zhang | Chen Ma | Guangxin Xia | Ping Li | Xing Sun | Jiaan Shao | Leduo Zhang | Yanjun Liu | Yufeng Li | Hailin Deng | Weixin Qi | Bojun Li | Jia Xu | Jian-sheng Han | Jingkang Shen